Skip to Content
Top

BY Scott Merville

An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial reported in the May 18 issue of The Lancet.

The drug dabrafenib, which targets the Val600 BRAF mutation that is active in half of melanoma cases, also cut the size of tumors in 25 of 36 patients with late-stage melanoma that had not spread...

BY Enica Jordan

MD Anderson has launched a new course on The Professional Oncology Education site. Colorectal Cancer Survivorship is funded by a grant from...

BY Scott Merville

Cancer stem cells, a small subgroup of hard-core tumor cells capable of both self-renewal and tumor generation, are hard to find, let alone...

BY Scott Merville

While discussion continues over the value of screening healthy men for prostate cancer by testing for levels of prostate specific antigen (PSA) in their blood, scientists have found another use for PSA.

Prostate cancer cells that express low levels of the protein give rise to cancer stem cells that are both hard to kill with existing drugs and highly capable of generating cancer cells on a large scale.

A team of scientists...

BY Scott Merville

When 3,000 participants lineup Saturday for the 15th annual Sprint for Life 5K Run/Walk and Sprint for Sprouts Kids' Run they'll take thousands...